Filtered By:
Specialty: Health Management
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia
CONCLUSIONS: Doubling the number of patients with AIS who are thrombolyzed would lead to reductions in the number of patients with sequelae and would require a budgetary effort of 5.5-7.0%. The early initiation of treatment (0-180minutes) gives an additional benefit in reducing the number of sequelae and a lower budgetary impact than initiation within the last time window (181-270minutes).PMID:35702977 | DOI:10.1080/14737167.2022.2089655
Source: Expert Review of Pharmacoeconomics and Outcomes Research - June 15, 2022 Category: Health Management Authors: Yaneth Gil-Rojas Pieralessandro Lasalvia Source Type: research
